Stockscreener 앱 받기
70.13
0.16%
0.11
시간 외 거래:
69.75
-0.38
-0.54%
전일 마감가:
$70.02
열려 있는:
$71.27
하루 거래량:
667.09K
Relative Volume:
0.89
시가총액:
$4.45B
수익:
-
순이익/손실:
$-159.39M
주가수익비율:
-19.81
EPS:
-3.5401
순현금흐름:
$-105.22M
1주 성능:
-2.52%
1개월 성능:
+804.90%
6개월 성능:
+1,013%
1년 성능:
+524.49%
1일 변동 폭
$68.50
$72.98
1주일 범위
$67.09
$72.98
52주 변동 폭
$4.77
$75.51
Abivax Adr Stock (ABVX) Company Profile
ABVX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
70.13 | 5.22B | 0 | -159.39M | -105.22M | -3.5401 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-03-20 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-12-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-29 | 개시 | Laidlaw | Buy |
| 2024-05-20 | 개시 | BTIG Research | Buy |
| 2024-04-29 | 개시 | Guggenheim | Buy |
| 2024-04-29 | 개시 | Piper Sandler | Overweight |
| 2023-11-14 | 개시 | Leerink Partners | Outperform |
| 2023-11-14 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Abivax Adr 주식(ABVX)의 최신 뉴스
2 Beaten-Down Stocks With Incredible Upside Potential - The Motley Fool
Abivax (NASDAQ:ABVX) Stock Price Up 5.2% on Analyst Upgrade - Defense World
Leerink Partnrs Brokers Reduce Earnings Estimates for Abivax - Defense World
Lifesci Capital Brokers Lift Earnings Estimates for Abivax - Defense World
Brokerages Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Price Target at $78.75 - Defense World
Abivax SA Announces $608.6 Million Public Offering of ADSs - The Globe and Mail
Abivax (NASDAQ:ABVX) Reaches New 52-Week High on Analyst Upgrade - Defense World
Abivax SA Stock Surges on Promising Drug Results - TipRanks
Abivax (NASDAQ:ABVX) Trading 577.5% Higher on Analyst Upgrade - Defense World
Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating - TipRanks
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS), Abivax SA Sponsored ADR (ABVX) and Kyowa Kirin Co (OtherKYKOF) - The Globe and Mail
Abivax (NASDAQ:ABVX) Hits New 52-Week High on Analyst Upgrade - Defense World
Abivax Hits The Stratosphere, Up Nearly 600%, On 'Potentially Disruptive' Results - Investor's Business Daily
10 Best First Jobs for Aspiring CEOs - inkl
Prologis Inc (PLD) Stock: Navigating Drops and Gains - investchronicle.com
Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod - TipRanks
Abivax Reports Positive Phase 3 Results for Ulcerative Colitis Treatment - TipRanks
Grid Metals (CVE:GRDM) Shares Up 44.4% – Here’s What Happened - Defense World
The ICU Stock Puzzle: Unraveling SeaStar Medical Holding Corp’s Fluctuating Performance - investchronicle.com
Citizens JMP reiterates Market Outperform rating on Abivax stock - Investing.com India
Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact - TipRanks
Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analyst Coverage Updates - The Globe and Mail
Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease - TipRanks
Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends - TipRanks
Abivax SA Shareholders Approve 2024 Financials and Board Appointments - TipRanks
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Galapagos (GLPG) and Tenet Healthcare (THC) - The Globe and Mail
European ADRs Edge Up As Wisekey And ASML Lead Gains - Finimize
Promising Outlook for Abivax’s Obefazimod in Ulcerative Colitis with Upcoming Phase 3 Results as Key Catalyst - TipRanks
Abivax SA Reports Increased Losses Amid R&D Expansion - TipRanks
Abivax Reports First Quarter 2025 Financial Results with Increased R&D Costs - TipRanks
Optimistic Buy Rating for Abivax SA: Obefazimod’s Potential in Ulcerative Colitis and Market Opportunity - TipRanks
Abivax Completes Enrollment for Phase 3 Ulcerative Colitis Trials - TipRanks
Abivax Announces AGM Details and Board Appointment Amid 2025 Milestones - TipRanks
Abivax ADR (NASDAQ: ABVX) – Does It Provide Stability And Growth? - Stocksregister
Abivax Reports 2024 Financial Results, Eyes Clinical Milestones - TipRanks
Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating - TipRanks
Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength - TipRanks
Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment - TipRanks
Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position - TipRanks
Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 - TipRanks
Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High? - MSN
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year? - Nasdaq
Abivax Adr (ABVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):